Yousif Capital Management LLC Sells 1,384 Shares of DaVita Inc. (NYSE:DVA)

Yousif Capital Management LLC reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 11.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,578 shares of the company’s stock after selling 1,384 shares during the quarter. Yousif Capital Management LLC’s holdings in DaVita were worth $1,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of DVA. PNC Financial Services Group Inc. increased its position in DaVita by 1.0% during the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock valued at $1,426,000 after acquiring an additional 153 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in DaVita during the fourth quarter valued at $2,831,000. Raymond James & Associates increased its position in DaVita by 135.2% during the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock valued at $3,601,000 after acquiring an additional 19,759 shares during the last quarter. Handelsbanken Fonder AB increased its position in DaVita by 108.8% during the fourth quarter. Handelsbanken Fonder AB now owns 16,700 shares of the company’s stock valued at $1,749,000 after acquiring an additional 8,700 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in DaVita by 27.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company’s stock valued at $5,341,000 after acquiring an additional 11,097 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on DVA shares. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 25th. Truist Financial upped their price target on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. UBS Group upped their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, Barclays initiated coverage on DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $118.50.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,540 shares of company stock valued at $16,551,071. Insiders own 1.40% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $134.45 on Friday. The business has a 50-day moving average price of $133.71 and a 200-day moving average price of $112.59. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $145.04. The firm has a market cap of $11.79 billion, a price-to-earnings ratio of 15.28, a price-to-earnings-growth ratio of 1.20 and a beta of 1.04. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 66.59% and a net margin of 6.61%. The company had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same period in the prior year, the company earned $1.58 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts predict that DaVita Inc. will post 9.49 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.